✦ LIBER ✦
Phase III, Randomized, Open-Label Study of Daily Imatinib Mesylate 400 mg Versus 800 mg in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase Using Molecular End Points: Tyrosine Kinase Inhibitor Optimization and Selectivity Study
✍ Scribed by Cortes, J. E.; Baccarani, M.; Guilhot, F.; Druker, B. J.; Branford, S.; Kim, D.-W.; Pane, F.; Pasquini, R.; Goldberg, S. L.; Kalaycio, M.; Moiraghi, B.; Rowe, J. M.; Tothova, E.; De Souza, C.; Rudoltz, M.; Yu, R.; Krahnke, T.; Kantarjian, H. M.; Radich, J. P.; Hughes, T. P.
- Book ID
- 124089554
- Publisher
- American Society of Clinical Oncology
- Year
- 2010
- Tongue
- English
- Weight
- 166 KB
- Volume
- 28
- Category
- Article
- ISSN
- 0732-183X
No coin nor oath required. For personal study only.